Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Every developer should be paying attention to the local-first architecture movement and what it means for JavaScript. Here’s ...

Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...

After presenting comparable docking results last year—and using them to prospectively identify drug candidates on difficult targets—Deep Origin welcomes Isomorphic Labs to the frontier SOUTH SAN ...

The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the shape of biological life to actively engineering its functions. While ...

US oil buoys Swiss fossil fuel needs amid Middle East conflict Read more: US oil buoys Swiss fossil fuel needs amid Middle East conflict Swiss companies export military equipment worth almost CHF1 ...

(MENAFN- Swissinfo) Google DeepMind spin-off Isomorphic Labs is building an AI drug design engine that it believes can“solve” all diseases. We spoke to its Chief Technology Officer in Lausanne about ...

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Jan 20 (Reuters) - Isomorphic Labs, ‌which uses artificial intelligence ‌for drug discovery, expects to have its first clinical trials by the ‍end of 2026, founder and CEO Demis Hassabis said ⁠on ...